Sign Out
Asthma: 80/4.5 mcg and 320/9 mcg: Symbicort is indicated in the treatment of asthma where use of a combination (inhaled corticosteroid and long acting β2 adrenoceptor agonist) is appropriate: patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short acting β2 adrenoceptor agonists; or patients already adequately controlled on both inhaled corticosteroids and long acting β2 adrenoceptor agonists.
Note: Symbicort Turbuhaler 80/4.5 micrograms/inhalation is not appropriate in patients with severe asthma.
160/4.5 mcg: Symbicort Turbuhaler 160/4.5 mcg is indicated in adults and adolescents (12 years and older), for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see Dosage & Administration).
Chronic Obstructive Pulmonary Disease (COPD): 160/4.5 mcg and 320/9 mcg: Symptomatic treatment of patients with COPD with FEV1 <70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy (see also Precautions).
Continue with Google